Zai Lab’s (NASDAQ:ZLAB) lock-up period will end on Monday, March 19th. Zai Lab had issued 8,333,333 shares in its initial public offering on September 20th. The total size of the offering was $149,999,994 based on an initial share price of $18.00. After the expiration of Zai Lab’s lock-up period, company insiders and major shareholders will be able to sell their shares of the company.
A number of equities research analysts recently issued reports on the stock. BidaskClub raised shares of Zai Lab from a “sell” rating to a “hold” rating in a research note on Wednesday, January 31st. JPMorgan Chase & Co. raised shares of Zai Lab from a “neutral” rating to an “overweight” rating and set a $32.00 price target on the stock in a research note on Wednesday, February 14th.
Shares of Zai Lab (NASDAQ:ZLAB) opened at $22.10 on Monday. Zai Lab has a 12 month low of $19.80 and a 12 month high of $35.74.
COPYRIGHT VIOLATION WARNING: This report was reported by Markets Daily and is the sole property of of Markets Daily. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://www.themarketsdaily.com/2018/03/12/zai-lab-ltds-lock-up-period-to-end-on-march-19th-nasdaqzlab.html.
About Zai Lab
Zai Lab Ltd, incorporated on March 28, 2017, is a biopharmaceutical company. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including in the fields of oncology, autoimmune and infectious diseases.
Receive News & Ratings for Zai Lab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zai Lab and related companies with MarketBeat.com's FREE daily email newsletter.